vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $359.9M, roughly 1.4× AdvanSix Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -0.8%, a 7.6% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs -1.7%). Over the past eight quarters, AdvanSix Inc.'s revenue compounded faster (3.4% CAGR vs -0.1%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ASIX vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $493.8M |
| Net Profit | $-2.8M | $33.7M |
| Gross Margin | 7.6% | — |
| Operating Margin | -0.7% | 9.9% |
| Net Margin | -0.8% | 6.8% |
| Revenue YoY | 9.4% | -1.7% |
| Net Profit YoY | -892.9% | 10.5% |
| EPS (diluted) | $-0.11 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $493.8M | ||
| Q3 25 | $374.5M | $492.9M | ||
| Q2 25 | $410.0M | $468.8M | ||
| Q1 25 | $377.8M | $458.4M | ||
| Q4 24 | $329.1M | $502.4M | ||
| Q3 24 | $398.2M | $511.2M | ||
| Q2 24 | $453.5M | $504.3M | ||
| Q1 24 | $336.8M | $495.1M |
| Q4 25 | $-2.8M | $33.7M | ||
| Q3 25 | $-2.6M | $71.7M | ||
| Q2 25 | $31.4M | $39.3M | ||
| Q1 25 | $23.3M | $20.7M | ||
| Q4 24 | $352.0K | $30.5M | ||
| Q3 24 | $22.3M | $19.4M | ||
| Q2 24 | $38.9M | $-153.0M | ||
| Q1 24 | $-17.4M | $4.0M |
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | -0.7% | 9.9% | ||
| Q3 25 | -0.9% | 13.8% | ||
| Q2 25 | 7.7% | 12.8% | ||
| Q1 25 | 7.7% | 7.0% | ||
| Q4 24 | -3.9% | 7.8% | ||
| Q3 24 | 7.5% | 6.6% | ||
| Q2 24 | 11.5% | -31.3% | ||
| Q1 24 | -7.0% | 3.2% |
| Q4 25 | -0.8% | 6.8% | ||
| Q3 25 | -0.7% | 14.5% | ||
| Q2 25 | 7.7% | 8.4% | ||
| Q1 25 | 6.2% | 4.5% | ||
| Q4 24 | 0.1% | 6.1% | ||
| Q3 24 | 5.6% | 3.8% | ||
| Q2 24 | 8.6% | -30.3% | ||
| Q1 24 | -5.2% | 0.8% |
| Q4 25 | $-0.11 | $0.40 | ||
| Q3 25 | $-0.10 | $0.84 | ||
| Q2 25 | $1.15 | $0.46 | ||
| Q1 25 | $0.86 | $0.24 | ||
| Q4 24 | $0.02 | $0.37 | ||
| Q3 24 | $0.82 | $0.23 | ||
| Q2 24 | $1.43 | $-1.84 | ||
| Q1 24 | $-0.65 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $815.2M | $865.9M |
| Total Assets | $1.7B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $375.2M | ||
| Q3 25 | $23.7M | $340.1M | ||
| Q2 25 | $18.4M | $224.7M | ||
| Q1 25 | $8.3M | $99.0M | ||
| Q4 24 | $19.6M | $229.9M | ||
| Q3 24 | $17.3M | $103.8M | ||
| Q2 24 | $12.1M | $19.4M | ||
| Q1 24 | $20.6M | $8.0M |
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $815.2M | $865.9M | ||
| Q3 25 | $818.2M | $890.7M | ||
| Q2 25 | $823.7M | $833.8M | ||
| Q1 25 | $794.4M | $789.2M | ||
| Q4 24 | $774.6M | $764.9M | ||
| Q3 24 | $766.4M | $732.5M | ||
| Q2 24 | $746.6M | $706.5M | ||
| Q1 24 | $713.2M | $856.2M |
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $2.1B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.5B | $2.0B | ||
| Q1 24 | $1.5B | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $114.1M |
| Free Cash FlowOCF − Capex | $36.1M | — |
| FCF MarginFCF / Revenue | 10.0% | — |
| Capex IntensityCapex / Revenue | 7.7% | — |
| Cash ConversionOCF / Net Profit | — | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $114.1M | ||
| Q3 25 | $26.6M | $137.3M | ||
| Q2 25 | $21.1M | $137.2M | ||
| Q1 25 | $11.4M | $-117.5M | ||
| Q4 24 | $64.2M | $133.0M | ||
| Q3 24 | $57.3M | $91.8M | ||
| Q2 24 | $50.2M | $107.0M | ||
| Q1 24 | $-36.2M | $-125.2M |
| Q4 25 | $36.1M | — | ||
| Q3 25 | $66.0K | — | ||
| Q2 25 | $-7.2M | — | ||
| Q1 25 | $-22.6M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | — | ||
| Q2 24 | $16.7M | — | ||
| Q1 24 | $-71.6M | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | -1.7% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | -21.3% | — |
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.4% | — | ||
| Q1 24 | 10.5% | — |
| Q4 25 | — | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | 0.67× | 3.49× | ||
| Q1 25 | 0.49× | -5.66× | ||
| Q4 24 | 182.29× | 4.36× | ||
| Q3 24 | 2.57× | 4.72× | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
